Analytical Data
-
Gene name
4-1BB/TNFRSF9
- Application
-
Alternative Names
CD137; CDw137; 4-1BB; ILA; Induced By Lymphocyte Activation; T-cell antigen 4-1BB homolog
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P20334
-
Expression Region
Val24~Pro179
-
Molecular Weight
20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Related Products
Protein Description
4-1BB, also known as TNFRSF9, is a member of the tumor necrosis factor receptor (TNFR) superfamily and plays a crucial role in enhancing T cell activation and survival, making it a significant target for cancer immunotherapy. Research has shown that 4-1BB expression is upregulated on activated T cells, suggesting its involvement in the costimulatory signals that promote T cell proliferation and cytotoxic activity against tumor cells. The interest in 4-1BB as a therapeutic target has intensified with the development of recombinant proteins, including agonistic antibodies and fusion proteins, aimed at stimulating the 4-1BB signaling pathway to boost anti-tumor immune responses. Studies have indicated that targeting 4-1BB can lead to improved antitumor activity and prolonged survival in various preclinical models. Moreover, the combination of 4-1BB agonists with other immunotherapeutic agents, such as checkpoint inhibitors, has shown promise in enhancing overall treatment efficacy. Understanding the structural and functional dynamics of 4-1BB is essential for the rational design of these therapeutic agents. Consequently, ongoing research into the mechanisms of action, optimal dosing regimens, and potential synergies with existing treatments will be critical for translating findings into clinical applications, ultimately aiming to improve therapeutic outcomes for cancer patients.
